HRP20120473T1 - Agonisti ppar gama za indukciju ekspresije kationskog antimikrobnog peptida kao imuno zaštitni stimulansi - Google Patents

Agonisti ppar gama za indukciju ekspresije kationskog antimikrobnog peptida kao imuno zaštitni stimulansi Download PDF

Info

Publication number
HRP20120473T1
HRP20120473T1 HRP20120473AT HRP20120473T HRP20120473T1 HR P20120473 T1 HRP20120473 T1 HR P20120473T1 HR P20120473A T HRP20120473A T HR P20120473AT HR P20120473 T HRP20120473 T HR P20120473T HR P20120473 T1 HRP20120473 T1 HR P20120473T1
Authority
HR
Croatia
Prior art keywords
propionic acid
compound
immunoprotective
ppar
stimulants
Prior art date
Application number
HRP20120473AT
Other languages
English (en)
Inventor
Sergio@Baroni
Pierre@Desreumaux
Salvatore@Bellinvia
Original Assignee
Giuliani@International@Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani@International@Limited filed Critical Giuliani@International@Limited
Publication of HRP20120473T1 publication Critical patent/HRP20120473T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4721—Cationic antimicrobial peptides, e.g. defensins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)

Abstract

Spoj izabran između metoksi aminofenil propionske kiseline amino N hidroksi metoksibenzamida etoksi aminofenil propionske kiseline ili etoksi aminofenil propionske kiseline za uporabu u liječenju i ili prevenciji akutnog divertikulitisa Patent sadrži još patentna zahtjeva

Claims (5)

1. Spoj izabran između 2-metoksi-3-(4’-aminofenil)propionske kiseline, 5-amino-N-hidroksi-2-metoksibenzamida, 2-etoksi-3-(4’-aminofenil)propionske kiseline ili 2-etoksi-3-(3’-aminofenil)propionske kiseline za uporabu u liječenju i/ili prevenciji akutnog divertikulitisa.
2. Spoj prema patentnom zahtjevu 1 za uporabu prema patentnom zahtjevu 1, pri čemu je liječenje i/ili prevencija akutnog divertikulitisa kod bolesnika pogođenih divertikulozom debelog crijeva, neodređenim kolitisom i infektivnim kolitisom.
3. Spoj prema patentnom zahtjevu 1 za uporabu prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, pri čemu je spoj 2-metoksi-3-(4’-aminofenil)propionska kiselina.
4. Spoj prema patentnom zahtjevu 3 za uporabu prema patentnom zahtjevu 3, pri čemu je spoj prisutan u racemičnoj smjesi ili je prisutan kao S- ili R- enantiomer.
5. Spoj prema patentnom zahtjevu 4 za uporabu prema patentnom zahtjevu 4, pri čemu je spoj prisutan u smjesi koja sadrži višak jednog enantiomera u odnosu na drugi.
HRP20120473AT 2007-02-28 2012-06-05 Agonisti ppar gama za indukciju ekspresije kationskog antimikrobnog peptida kao imuno zaštitni stimulansi HRP20120473T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE20070129A IE20070129A1 (en) 2007-02-28 2007-02-28 Ppar-gamma agonists stimulate enteric defensin expression
PCT/EP2008/052354 WO2008104557A1 (en) 2007-02-28 2008-02-27 Ppar-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants

Publications (1)

Publication Number Publication Date
HRP20120473T1 true HRP20120473T1 (hr) 2012-07-31

Family

ID=39358381

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120473AT HRP20120473T1 (hr) 2007-02-28 2012-06-05 Agonisti ppar gama za indukciju ekspresije kationskog antimikrobnog peptida kao imuno zaštitni stimulansi

Country Status (19)

Country Link
US (1) US20110152225A1 (hr)
EP (1) EP2131829B1 (hr)
JP (1) JP5351772B2 (hr)
AR (1) AR065525A1 (hr)
AT (1) ATE553759T1 (hr)
AU (1) AU2008220762B2 (hr)
BR (1) BRPI0807377A8 (hr)
CA (1) CA2678159C (hr)
CY (1) CY1113000T1 (hr)
DK (1) DK2131829T3 (hr)
ES (1) ES2384195T3 (hr)
HR (1) HRP20120473T1 (hr)
IE (1) IE20070129A1 (hr)
MX (1) MX2009009006A (hr)
PL (1) PL2131829T3 (hr)
PT (1) PT2131829E (hr)
RS (1) RS52251B (hr)
SI (1) SI2131829T1 (hr)
WO (1) WO2008104557A1 (hr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
GB0821687D0 (en) * 2008-11-28 2008-12-31 Secr Defence Peptides
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
JP5715070B2 (ja) * 2009-02-16 2015-05-07 ノグラ ファーマ リミテッド アルキルアミド化合物およびその使用
KR101898610B1 (ko) 2010-08-31 2018-09-14 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도
JP6301844B2 (ja) * 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
MX2014012652A (es) * 2012-04-18 2014-11-25 Nogra Pharma Ltd Metodo de tratamiento de la intolerancia a la lactosa.
US20190046490A1 (en) * 2016-02-26 2019-02-14 Nogra Pharma Limited Methods of treating lactose intolerance
WO2019199979A1 (en) * 2018-04-10 2019-10-17 The General Hospital Corporation Antibacterial compounds
BR112021015609A2 (pt) 2019-02-08 2021-10-05 Nogra Pharma Limited Processo de fabricação de ácido 3-(4?-aminofenil)-2-metoxipropiônico, e análogos e intermediários do mesmo
CN116548385B (zh) * 2023-04-20 2023-10-27 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 自发型系统性红斑狼疮动物模型的构建方法及应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466012A (en) * 1891-12-29 Manufacture of posts
US1179533A (en) * 1910-04-20 1916-04-18 Maurice Lachman Pole.
US1034760A (en) * 1912-02-14 1912-08-06 Friedrich Georg Franz Braeckerbohm Mast for radiotelegraphy.
US1200453A (en) * 1915-12-22 1916-10-10 Bates Expanded Steel Truss Co Metallic pole.
US1616931A (en) * 1925-10-10 1927-02-08 Percy H Thomas Transmission tower for electric circuits
US2064121A (en) * 1933-10-23 1936-12-15 Lapp Insulator Company Inc Insulator for radio masts
US2116368A (en) * 1936-07-21 1938-05-03 Blaw Knox Co Antenna tower
US2401799A (en) * 1941-08-04 1946-06-11 Union Metal Mfg Co Radio antenna tower
US2410246A (en) * 1943-04-17 1946-10-29 Masts Ltd Mast, pole, and the like
US3196990A (en) * 1961-03-23 1965-07-27 Mc Graw Edison Co Tapered structural member and method of making the same
US3343315A (en) * 1964-08-04 1967-09-26 Aluminium Lab Ltd Guyed y tower
US3504464A (en) * 1966-03-07 1970-04-07 Kaiser Aluminium Chem Corp Tower structure and method of erecting the same
US3571991A (en) * 1969-02-06 1971-03-23 Anderson Electric Corp Metal pole
JPS4860435A (hr) * 1971-11-30 1973-08-24
US3935689A (en) * 1974-04-01 1976-02-03 Contran Corporation Transmission line structure
US4314434A (en) * 1977-07-07 1982-02-09 Meisberger Raymond F Utility line support structure
US4431375A (en) * 1979-05-10 1984-02-14 Carter Wind Power Wind-driven generator apparatus
US5319901A (en) * 1991-06-14 1994-06-14 Goldsworthy W Brandt Bifurcated column joint system for electrical transmission tower
NZ224087A (en) * 1987-04-01 1990-08-28 Dak Lab As Topical pharmaceutical compositions containing 4- or 5- amino salicylic acid or a functional derivative thereof
DE68919009T2 (de) * 1988-05-05 1995-02-23 Tillotts Pharma Ag Verwendung von 5-Amino-salicylsäure für die Behandlung von Hautkrankheiten.
US6286281B1 (en) * 1991-06-14 2001-09-11 David W. Johnson Tubular tapered composite pole for supporting utility lines
US5687537A (en) * 1996-05-24 1997-11-18 Pi Rod Inc. Modular antenna pole
US5880404A (en) * 1996-06-28 1999-03-09 Advanced Metals Technology Corporation Power transmission support structures
GB9617001D0 (en) * 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
US6114382A (en) * 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6343445B1 (en) * 2000-03-07 2002-02-05 General Signal Corporation Tower structure
TWI249519B (en) * 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
US6668498B2 (en) * 2000-12-13 2003-12-30 Ritz Telecommunications, Inc. System and method for supporting guyed towers having increased load capacity and stability
JP2003095938A (ja) * 2001-09-21 2003-04-03 Masami Moriyama 抗菌ペプチド分泌誘発剤
JP2004107302A (ja) * 2002-09-20 2004-04-08 Masami Moriyama 過敏性腸症候群治療薬
US7059095B1 (en) * 2002-10-11 2006-06-13 Stevens James A Anchored monopole upgrade system
US7119079B2 (en) * 2003-01-22 2006-10-10 Barbeau Donald L Bioadhesive pharmaceutical compositions
GB0303609D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US6952058B2 (en) * 2003-02-20 2005-10-04 Wecs, Inc. Wind energy conversion system
CA2424599A1 (en) * 2003-04-04 2004-10-04 Andre Rioux Modular tower structure
US7592300B2 (en) * 2003-11-24 2009-09-22 The Dial Corporation Antimicrobial compositions containing an aromatic carboxylic acid and a hydric solvent
ITRM20050390A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.

Also Published As

Publication number Publication date
JP2010520166A (ja) 2010-06-10
AU2008220762B2 (en) 2013-08-22
EP2131829A1 (en) 2009-12-16
CY1113000T1 (el) 2016-04-13
AR065525A1 (es) 2009-06-10
MX2009009006A (es) 2010-02-03
EP2131829B1 (en) 2012-04-18
PL2131829T3 (pl) 2012-08-31
RS52251B (en) 2012-10-31
ES2384195T3 (es) 2012-07-02
IE20070129A1 (en) 2008-12-24
PT2131829E (pt) 2012-06-20
ATE553759T1 (de) 2012-05-15
DK2131829T3 (da) 2012-05-29
CA2678159C (en) 2015-07-21
SI2131829T1 (sl) 2012-09-28
AU2008220762A1 (en) 2008-09-04
BRPI0807377A8 (pt) 2016-11-16
JP5351772B2 (ja) 2013-11-27
BRPI0807377A2 (pt) 2014-05-06
WO2008104557A1 (en) 2008-09-04
CA2678159A1 (en) 2008-09-04
US20110152225A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
HRP20120473T1 (hr) Agonisti ppar gama za indukciju ekspresije kationskog antimikrobnog peptida kao imuno zaštitni stimulansi
HRP20110861T1 (hr) Lijek za liječenje gripe
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
HRP20110451T1 (hr) Upotreba izotiocijanata kao sredstva protiv mieloma
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
BRPI0913457A2 (pt) "composto, composição farmacêutica, e, uso do composto"
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
BR112014025564B8 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma
NZ610911A (en) Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
ATE446744T1 (de) Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit
MY146614A (en) Shading composition
BR112013025881A2 (pt) composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii)
RS53312B (en) TERNARY HERBICIDE COMPOSITIONS CONTAINING AMINOPYRALID AND IMAZAMOX
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
RS53089B (en) TREATMENTS FOR NEUROLOGICAL DISORDERS
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
WO2016007629A3 (en) Compositions and delivery methods for treating dental infections, inflammation, sensitivity, and for use in dental restorations
CL2008003016A1 (es) Composicion para tratamiento de lavanderia que comprende una base de tratamiento de lavanderia y desde 0,01 a 10% en peso de particulas de film laminar concavas coloreadas.
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
RS54158B1 (en) AMILOID BINDING AGENTS
RS54439B1 (en) PHARMACEUTICAL COMBINATION FOR TREATMENT OF PAIN
BRPI0807597B8 (pt) composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
MX2021011823A (es) Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina.
GEP20217279B (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS AND THEIR USE